内源性一氧化氮合酶抑制物:一种新的内皮功能不全预测因子

血管内皮功能不全是多种心血管疾病的共同病理基础 .内源性一氧化氮合酶 (NOS)抑制物能阻止内皮细胞 (NO)合成 ,导致血管内皮功能降低 .高血压 ,动脉粥样硬化 ,糖尿病血管并发症等心血管疾病的内皮功能不全与内源性 NOS抑制物含量升高密切相关 .内源性 NOS抑制物可作为内皮功能不全的预测因子 ;阻止或抑制内源性 NOS抑制物生成可能是寻找防治心血管疾病药物的新途径 .

Endogenous inhibitor of nitric oxide synthase, new predictor of endothelial dysfunction

Endothelial dysfunction is a common pathological phenomenon for many cardiovascular diseases. Endogenous inhibitor of nitric oxide synthase, dimethylarginine, blocks the synthesis of nitric oxide in endothelial cells, leading to endothelial dysfunction. There is increasing evidence that endothelial dysfunction of many cardiovascular diseases, such as atherosclerosis, hypertension, congestive heart failure, and diabetic vascular complication, closely relates to the elevation of endogenous inhibitor of nitric oxide synthase in plasma. The endogenous inhibitor of nitric oxide synthase may therefore act as a predictor for endothelial dysfunction, and to inhibit the production of endogenous inhibitor of nitric oxide synthase may be a new pathway for looking for drugs to treat and prevent cardiovascular diseases.